首页> 外文期刊>Antiviral Research >Inhibition of SARS-CoV replication by siRNA.
【24h】

Inhibition of SARS-CoV replication by siRNA.

机译:siRNA抑制SARS-CoV复制。

获取原文
获取原文并翻译 | 示例
       

摘要

Serious outbreaks of severe acute respiratory syndrome (SARS), caused by the newly discovered coronavirus SARS-CoV, occurred between late 2002 and early 2003 and there is an urgent need for effective antiviral agents. RNA interference in animals and post-transcriptional gene silencing plants is mediated by small double-stranded RNA molecules named small interfering RNA (siRNA). Recently, siRNA-induced RNA interference(RNAi) may provide a new approach to therapy for pathogenic viruses, e.g. HIV and HCV. In this study, the silencing potential of seven synthetic siRNAs against SARS-CoV leader, TRS, 3'-UTR and Spike coding sequence have been applied to explore the possibility for prevention of SARS-CoV infection. We demonstrate that siRNAs directed against Spike sequences and the 3'-UTR can inhibit the replication of SARS-CoV in Vero-E6 cells, and holds out promise for the development of an effective antiviral agent against SARS-CoV.
机译:由新发现的冠状病毒SARS-CoV引起的严重急性呼吸道综合症(SARS)的严重暴发发生在2002年底至2003年初之间,迫切需要有效的抗病毒药物。动物和转录后基因沉默植物中的RNA干扰是由称为小干扰RNA(siRNA)的小双链RNA分子介导的。最近,siRNA诱导的RNA干扰(RNAi)可能为治疗病原性病毒提供新的方法。 HIV和HCV。在这项研究中,七个合成的siRNA对SARS-CoV前导序列,TRS,3'-UTR和Spike编码序列的沉默潜力已被用于探索预防SARS-CoV感染的可能性。我们证明了针对Spike序列和3'-UTR的siRNA可以抑制SARS-CoV在Vero-E6细胞中的复制,并为开发抗SARS-CoV的有效抗病毒剂提供了希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号